Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
The American Journal of Medicine
|
September 16, 1991
Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System
D H Culver, T C Horan, R P Gaynes, et al.
The American Journal of Medicine
|
September 16, 1991
Nosocomial infections in elderly patients in the United States, 1986-1990. National Nosocomial Infections Surveillance System
T G Emori, S N Banerjee, D H Culver, et al.
Plos One
|
January 4, 2013
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat
Ryan M Fryer, Akalushi Muthukumarana, Paul C Harrison, et al.
Journal of the American Chemical Society
|
November 15, 2002
The practical synthesis of a novel and highly potent analogue of bryostatin
Paul A Wender, Jeremy L Baryza, Chad E Bennett, et al.
Anticancer Research
|
October 28, 2015
Antitumor Activity of 3-Indolylmethanamines 31B and PS121912
Margaret L Guthrie, Preetpal S Sidhu, Emily K Hill, et al.
Plos One
|
April 18, 2012
Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model
Richard G Moore, Thilo S Lange, Katina Robinson, et al.
Genes & Cancer
|
January 4, 2014
PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models
Nada Kawar, Shannon Maclaughlan, Timothy C Horan, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 23, 2014
Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists
Joshua C Horan, Sulagna Sanyal, Younggi Choi, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
The American Journal of Medicine
|
September 16, 1991
Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System
D H Culver, T C Horan, R P Gaynes, et al.
The American Journal of Medicine
|
September 16, 1991
Nosocomial infections in elderly patients in the United States, 1986-1990. National Nosocomial Infections Surveillance System
T G Emori, S N Banerjee, D H Culver, et al.
Plos One
|
January 4, 2013
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat
Ryan M Fryer, Akalushi Muthukumarana, Paul C Harrison, et al.
Journal of the American Chemical Society
|
November 15, 2002
The practical synthesis of a novel and highly potent analogue of bryostatin
Paul A Wender, Jeremy L Baryza, Chad E Bennett, et al.
Anticancer Research
|
October 28, 2015
Antitumor Activity of 3-Indolylmethanamines 31B and PS121912
Margaret L Guthrie, Preetpal S Sidhu, Emily K Hill, et al.
Plos One
|
April 18, 2012
Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model
Richard G Moore, Thilo S Lange, Katina Robinson, et al.
Genes & Cancer
|
January 4, 2014
PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models
Nada Kawar, Shannon Maclaughlan, Timothy C Horan, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 23, 2014
Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists
Joshua C Horan, Sulagna Sanyal, Younggi Choi, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Page
of 8